Aprea Therapeutics Inc APRE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if APRE is a good fit for your portfolio.
News
-
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
-
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
-
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
-
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
-
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
-
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
-
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
Trading Information
- Previous Close Price
- $5.73
- Day Range
- $5.61–5.61
- 52-Week Range
- $2.78–8.85
- Bid/Ask
- $5.61 / $5.99
- Market Cap
- $30.46 Mil
- Volume/Avg
- 998 / 37,005
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 7
- Website
- https://www.aprea.com
Valuation
|
Metric
|
APRE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.24 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
APRE
Financial Strength
|
Metric
|
APRE
|
|---|---|
Quick Ratio | 4.93 |
Current Ratio | 5.14 |
Interest Coverage | — |
Quick Ratio
APRE
Profitability
|
Metric
|
APRE
|
|---|---|
Return on Assets (Normalized) | −49.55% |
Return on Equity (Normalized) | −61.19% |
Return on Invested Capital (Normalized) | −66.62% |
Return on Assets
APRE
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xbtrkszt | Ztpcl | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lflrlwsy | Ndcstv | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vmxgzslqz | Rvdckcq | $98.1 Bil | |
MRNA
| Moderna Inc | Rqncbnvsv | Jqpkt | $39.7 Bil | |
ARGX
| argenx SE ADR | Vmtkbyf | Gfjz | $21.5 Bil | |
BNTX
| BioNTech SE ADR | Cfrkqwcmq | Nspmq | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mkzdntb | Ttsfgs | $18.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lqbqgwhy | Vljspp | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qkgwbcqnv | Dfhtdwg | $12.5 Bil | |
INCY
| Incyte Corp | Sxqvqdkts | Vywcr | $11.8 Bil |